Comparison of R-miniCHOP with R-Bendamustine (R-B) in diffuse large B-cell Lymphoma (DLBCL) in elderly and comorbid patients

被引：0
|
作者：
Hammersen, F. J. [1 ]
Ruethrich, M. M. [1 ]
Wedding, U. [2 ]
Sommer, M. [3 ]
Hochhaus, A. [1 ]
La Rosee, P. [4 ]
机构：
[1] Univ Klinikum Jena, Hamatol internist Onkol, Klin Innere Med 2, Jena, Germany
[2] Univ Klinikum Jena, Palliat Med, Klin Innere Med 2, Jena, Germany
[3] Inst Allgemeinmed Jena, Jena, Germany
[4] Schwarzwald Baar Klinikum Villingen Schwenningen, Klin Innere Med Onkol Hamatol Immunol Infektiol &, Villingen Schwenningen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P173
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [41] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Glass, B.
    Sehn, L. H.
    Herrera, A. F.
    Matasar, M.
    Kamdar, M.
    Assouline, S.
    Hertzberg, M.
    Kim, T. M.
    Kim, W. S.
    McMillan, A.
    Ozcan, M.
    Hirata, J.
    Penuel, E.
    Cheng, J.
    Ku, G.
    Flowers, C. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
  • [42] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [43] Excellent Outcomes with R-CEOP for Diffuse Large B-Cell Lymphoma in Elderly Patients Not Eligible for Anthracyclines
    Grech, M.
    Gauci, J.
    Theuma, K. -B.
    Gatt, A.
    Camilleri, D. -J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 86 - 87
  • [44] A New Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP
    Miura, Katsuhiro
    Konishi, Jun
    Miyake, Takaaki
    Masanori, Makita
    Hojo, Atsuko
    Masaki, Yasufumi
    Uno, Masatoshi
    Ozaki, Jun
    Yoshida, Chikamasa
    Niiya, Daigo
    Kitazume, Koichi
    Maeda, Yoshinobu
    Takizawa, Jun
    Sakai, Rika
    Nawa, Yuichiro
    Yano, Tomofumi
    Yamamoto, Kazuhiko
    Sunami, Kazutaka
    Hiramatsu, Yasushi
    Aoyama, Kazutoshi
    Tsujimura, Hideki
    Hatta, Yoshihiro
    Kanno, Masatoshi
    BLOOD, 2015, 126 (23)
  • [45] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Chen, Robert W.
    Ansel, Stephen Maxted
    Zinzani, Pier Luigi
    Vacirca, Jeffrey L.
    Lopez-Guillermo, Armando
    Hutchings, Martin
    Jurczak, Wojciech
    Hess, Georg
    Le Gouill, Steven
    Offner, Fritz
    Santoro, Armando
    Salles, Gilles A.
    Stypinski, Darla
    Laird, Douglas
    Pavlov, Dmitri
    Andreola, Giovanna
    Fly, Kolette D.
    Woolfson, Adrian
    Collins, Graham P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Descriptive analysis of the efficacity of R-GEMOX /R-IE/R-CEPP in patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL)
    Fulbert, Baptiste
    Vincent, Theo
    Clarenne, Justine
    Abdelouahab, Imman
    Le Bozec, Antoine
    Durot, Eric
    Slimano, Florian
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025,
  • [47] Influence of rituximab(R) -fludarabine(F) and R-bendamustine(B) therapy on the immune system in relapsed lymphoma
    Ito, Kaori
    Okamoto, Masataka
    Ando, Maiko
    Ando, Yosuke
    Suzuki, Eri
    Okamoto, Akinao
    Inaguma, Yoko
    Hayashi, Takahiro
    Yamada, Shigeki
    Emi, Nobuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 96 - 97
  • [48] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
    Maziarz, Richard T.
    Schuster, Stephen J.
    Romanov, Vadim V.
    Rusch, Elisha S.
    Signorovitch, James
    Ericson, Solveig G.
    Maloney, David G.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [49] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
12345